Keywords: epistem, loss, rises, enters, novartis, deal, uk-based

Epistem's loss rises, but enters Novartis deal

Article | 23 March 2009

Print This

UK-based Epistem, a company utilizing contract research revenue to fund the development of novel therapies based on epithelial stem cell ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in